So lets look at the $1B (assume it is AUD)
Relyvrio sales in 2023 were est at USD$380M <> AUD$587M
Relyvrio is ONLY available in the USA <> Monepantel seeking AU, EU, USA
Relyvrio had numerous customers drop off the treatment due to side effects <> Monepantel so far has very few adverse effects/well tolerated to date.
Relyvrio potential to extend life by average of 9 months (now not so true) <> Monepantel potentially double and more than than so the customer base per year increases (not passing away in 9 months, so on the treatment for much longer)
It may well be this statement that the ASX has taken as a please explain. We will see in time. I do think there is sufficient data to explain an AUD $1B potential annual sales but I can also see where the ASX is dubious too. Unlike us, I highly doubt they study the company fundamentals before demanding a please explain.
adreamer
- Forums
- ASX - By Stock
- PAA
- Ann: Trading Halt
Ann: Trading Halt, page-40
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M |
Open | High | Low | Value | Volume |
19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 135256 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 79851 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 135256 | 0.200 |
9 | 87953 | 0.195 |
13 | 840004 | 0.190 |
12 | 226560 | 0.185 |
18 | 352803 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 79851 | 3 |
0.210 | 269460 | 5 |
0.215 | 103895 | 2 |
0.220 | 506039 | 7 |
0.225 | 420666 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |